ibi363

Colorectal Cancer

Innovent Biologics (Suzhou) Co. Ltd.Phase 2Active

CC

46/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 59/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
Orectalip Sinphar Pharmaceutical Co., Ltd	Phase 4	BB
Eloxatin Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Phase 4	BB
FLUOROURACILUM UNICANCER	Phase 4	BB

View all 50 →

Same molecule, other indications

ibi363 is also rated in:

renal cell carcinomaDormant

CCC

Indicative ·

53 / 100

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Dormant

CCC

Indicative ·

53 / 100

EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.